Comprehensive Cost Estimation of an Enhanced Recovery Pathway in Hip and Knee Arthroplasty Using an Expanded Time-Driven Activity-Based Costing Framework
Thomas, Boogmans William, Wainwright Thomas Paula Beck da Silva, Etges Ana Filip, Roodhooft Brecht, Cardoen Sophie, Hoozée
Thomas, Boogmans
William, Wainwright Thomas
Paula Beck da Silva, Etges Ana
Filip, Roodhooft
Brecht, Cardoen
Sophie, Hoozée
Publication Type
Journal article with impact factor
Editor
Supervisor
Publication Year
2026-04
Journal
The Journal of Arthroplasty
Book
Publication Volume
Publication Issue
Publication Begin page
Publication End page
Publication Number of pages
Collections
Abstract
BACKGROUND: Total hip (THA) and total knee arthroplasty (TKA) are among the most frequently performed surgeries worldwide, creating a substantial financial burden. Enhanced Recovery After Surgery (ERAS) pathways aim to improve outcomes while reducing costs, aligning with the principles of Value-Based Healthcare (VBHC). Time-Driven Activity-Based Costing (TDABC) is recommended for VBHC cost calculation, yet its application to ERAS is rarely reported. This study calculated total and ERAS-related costs of a comprehensive ERAS pathway for THA and TKA using TDABC.
METHODS: A retrospective single-center cohort study (February to September 2023) was performed in Belgium for 99 THA and 120 TKA patients following an uncomplicated ERAS pathway. Using the TDABC method and the "TDABC in Healthcare Consortium" framework, costs from first surgical consultation until the 3-month follow-up were divided into five categories. Direct costs (medication and material) and TDABC-allocated costs (personnel, infrastructure, and departmental overheads) were aggregated to determine total and ERAS-related costs. All costs are reported in euros (EUR) and converted to United States dollars (USD) using the average exchange rate (1 EUR = 1.08 USD) for 2023.
RESULTS: The mean total costs were €6,682.3 ($7,216.9) for THA and €8,091.3 ($8,738.6) for TKA. Material and personnel accounted for approximately 90% of total pathway costs. The ERAS-related costs represented approximately 10% of total pathway costs (€673.7/ $727.6 THA; €744.2/ $803.7 TKA). The highest ERAS costs were noted in the preoperative phase, whereas postoperative elements (e.g., early mobilization) had relatively low costs.
CONCLUSION: The TDABC revealed that ERAS costs represented only 10% of the total pathway cost and highlighted key (ERAS) cost components for further pathway improvement. This study offers a TDABC framework to standardize cost evaluation and support ERAS implementation, optimization, and sustainability within VBHC strategies.
Research Projects
Organizational Units
Journal Issue
Keywords
32 Biomedical and Clinical Sciences, 3202 Clinical Sciences, Assistive Technology, Bioengineering, Clinical Research, Rehabilitation